1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

  • April 2016
  • -
  • La Merie Publishing
  • -
  • 74 pages

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update


This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of April 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Table Of Contents

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update


Table of Contents


1. CD19-Targeted Therapeutics:



  • Fc-Engineered CD19-Targeted Antibodies

  • CD19-Targeted Antibody-Drug Conjugates

  • CD19-Targeted Immunotoxin

  • Bispecific, CD19-Targeted and T-Cell Recruiting Monoclonal Antibodies

  • Other CD19-Targeted Bispecific Monoclonal Antibodes

  • Autologous CD19-Targeted Chimeric Antigen Receptor T-Cells

  • Allogeneic CD19-Targeted Chimeric Antigen Receptor T-Cells


2. Corporate CD19-Targeted Therapy Pipelines


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Natural Killer Cell Lymphomas Global Clinical Trials Review, H2, 2016

Natural Killer Cell Lymphomas Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Natural Killer Cell Lymphomas Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Natural Killer Cell Lymphomas Global Clinical Trials Review, H2, 2016" provides an overview ...

Stem Cell Transplantation Global Clinical Trials Review, H2, 2016

Stem Cell Transplantation Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • September 2016
  • by Global Data

Stem Cell Transplantation Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Stem Cell Transplantation Global Clinical Trials Review, H2, 2016" provides an overview ...

 B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2016

B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “ B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the B-Cell Non-Hodgkin Lymphoma. ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.